DRUGBRIGHT MINDS BIOSCIENCES INC.vs its industry peers
A metric-by-metric comparison of BRIGHT MINDS BIOSCIENCES INC. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DRUGThis | $279M#2 | — | — | — | — | — | — | — | — | — | 36.3%#3 | — |
| CTRVP | — | — | — | — | — | 37.3%#4 | — | -647.5%#9 | — | — | — | — |
| CVSI | — | — | — | — | -12.2%#4 | 60.0%#3 | -3.4%#2 | -61.0%#5 | -48.1%#4 | 5#1 | — | — |
| CYDY | — | — | — | — | -100.0%#5 | -1240.2%#10 | — | — | — | — | — | — |
| CYTOF | — | — | — | — | — | -96.4%#9 | — | -207.6%#8 | — | — | — | — |
| DERM | — | — | — | — | 11.1%#2 | 22.1%#5 | -13.3%#3 | -35.6%#3 | -30.3%#3 | — | 4.0%#4 | — |
| ECOC | — | — | — | — | 0.0%#3 | -61.3%#8 | -2416.0%#4 | -76.9%#6 | -68.5%#5 | — | — | — |
| EDSA | $38M#4 | — | 4.3x#3 | — | -100.0%#5 | -16.5%#6 | — | -81.6%#7 | — | — | 58.4%#1 | — |
| ELTP | — | — | — | — | 77.1%#1 | 1140.0%#2 | 33.0%#1 | 42.8%#2 | 38.9%#1 | 5#1 | — | — |
| ENLV | $166M#3 | 0.0x#1 | 0.1x#1 | — | — | 8329.2%#1 | — | 63.9%#1 | -0.6%#2 | — | -95.6%#5 | — |
| EPRX | $299M#1 | — | 3.6x#2 | — | — | -51.3%#7 | — | -47.0%#4 | — | — | 55.9%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice